Table 1.

Baseline patient characteristics

Variable	Total N (%)	Group A N (%)	Group B N (%)	P
Total patients	87 (100)	45 (100)	42 (100)
Age (years)
<60 years	63 (72.4)	32 (71.1)	31 (73.8)	.778
≥60 years	24 (27.6)	13 (28.9)	11 (26.2)
Mean (SD)	51.9 (12.2)	53.2 (12)	50.5 (12.4)	.316
Median (range)	54 (30, 78)	54 (30, 78)	53.5 (30, 78)
BMI (kg/m2):
18.5–24.9	13 (14.9)	6 (13.3)	7 (16.7)	.873
25–29.9	41 (47.1)	21 (46.7)	20 (47.6)
≥30	33 (37.9)	18 (40)	15 (35.7)
Mean (SD)	29.0 (4.4)	29.2 (4.2)	28.8 (4.8)	.670
Median (range)	27.8 (20.7, 44.7)	27.9 (21.9, 38.3)	27.7 (20.7, 44.7)
Not current smoker	87 (100)	45 (100)	42 (100)	NA
CAD	3 (3.4)	2 (4.4)	1 (2.4)	1.0
HTN	29 (33.3)	17 (37.8)	12 (28.6)	.327
Dyslipidemia	18 (20.7)	8 (17.8)	10 (23.8)	.487
DM	9 (10.3)	4 (8.9)	5 (11.9)	.733
No. of comorbidities
0	48 (55.2)	22 (48.9)	26 (61.9)	.082
1	24 (27.6)	17 (37.8)	7 (16.7)
2+	15 (17.2)	6 (13.3)	9 (21.4)
Hemoglobin A1C at baseline (%)
4–5.6% (normal)	55 (63.2)	28 (62.2)	27 (64.3)	.841
5.7–6.4% (pre-diabetes)	25 (28.7)	14 (31.1)	11 (26.2)
6.5% or higher (diabetes)	7 (8)	3 (6.7)	4 (9.5)
Mean (SD)	5.5 (0.6)	5.6 (0.6)	5.5 (0.6)	.609
Median (range)	5.5 (4.2, 7.4)	5.5 (4.2, 7.2)	5.4 (4.5, 7.4)
T-level (ng/dL)
Mean (SD)	513.8 (155.6)	524.1 (158.3)	502.8 (153.9)	.527
Median (range)	488 (307, 998)	486 (307, 998)	491.5 (314, 929)
PDE-5i response	(n = 42)	(n = 20)	(n = 22)
No	10 (23.8)	5 (25.0)	5 (22.7)	1.00
Yes	32 (76.2)	15 (75.0)	17 (77.3)
ED
Mild (IIEF-EF scores 17–25)	60 (69)	32 (71.1)	28 (66.7)	.654
Moderate (IIEF-EF scores 11–16)	27 (31)	13 (28.9)	14 (33.3)

BMI = body mass index; CAD = coronary artery disease; DM = diabetes mellitus; ED = erectile dysfunction; HTN = hypertension; IIEF-EF = International Index of Erectile Function-Erectile Function domain; NA = not applicable; PDE-5i = phosphodiesterase type 5 inhibitor.

Group A: 5 daily treatments (720 shocks/d). Group B: 3 times a week for 2 weeks (600 shocks/d).

P: P-value from the chi-square test, the Fisher's exact test, or the 2-sample Student's t test.